Click here to view the United Healthcare (UHC) Medical Policy Updates » September 2024 United…
Cigna Medical Policy Updates – December 2022
Click here to view the Cigna Medical Policy Updates »
December 2022 Cigna Medical Policy Policy Updates:
- Abatacept Intravenous
- Abatacept Subcutaneous
- Abdomen Imaging Guidelines
- Acyclovir 5% Ointment for Individual and Family Plans
- Aducanumab
- Albendazole for Individual and Family Plans
- Amifampridine
- Aminocaproic Acid for Individual and Family Plans
- Anesthesia and Facility Services for Dental Treatment
- Angiotensin Receptor Blockers
- Antiparkinson Agents
- Apomorphine (Kynmobi)
- Apremilast
- Attention Deficit Hyperactivity Disorder (ADHD) Stimulants
- Autism Spectrum Disorders/Pervasive Developmental Disorders: Assessment and Treatment
- Becaplermin
- Bedaquiline
- Beta Blockers
- Betaine for Individual and Family Plans
- Biventricular Pacing/Cardiac Resynchronization Therapy (CRT )
- Bone Mineral Density Measurement
- Breast Imaging Guidelines
- Breast Imaging Guidelines
- Brodalumab
- Cardiac Imaging Guidelines
- Cenegermin Ophthalmic Solution
- Chest Imaging Guidelines
- Chiropractic Care
- Chiropractic Care (CPG 278)
- Cholic Acid
- Cinacalcet for Individual and Family Plans
- Ciprofloxacin/fluocinolone for Individual and Family Plans
- Clinical Information to Establish Medical Necessity
- Clomiphene
- Collagenase for Individual and Family Plans
- Computerized Dynamic Posturography (CDP)
- COVID-19 Drug and Biologic Therapeutics
- COVID-19 Vaccine
- Cyclosporine Ophthalmic Products
- Cysteamine Bitartrate for Individual and Family Plans
- Dabigatran
- Deutetrabenazine
- Donepezil
- Drugs/Biologics Not Covered Unless Approved Under Medical Necessity Review Employer Group Plans: Standard, Performance, or Legacy Prescription Drug List
- Drugs/Biologics Not Covered Unless Approved Under Medical Necessity Review Employer Group Plans: Value, Advantage, or Cigna Total Savings Prescription Drug List
- Elivaldogene autotemcel
- Epoetin Alfa Products
- Eptinezumab
- Erenumab
- Exhaled Nitric Oxide in the Management of Respiratory Disorders
- Fecal Bacteriotherapy
- Fingolimod
- Fostemsavir
- Fremanezumab
- Galcanezumab
- Ganaxolone
- Gender Dysphoria Treatment
- Genetic Testing for Hereditary and Multifactorial Conditions
- Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis
- Glatiramer
- Gonadotropin-Releasing Hormone (GnRH) Antagonists for Infertility Use
- Guselkumab
- Head Imaging Guidelines
- Immunomodulators – Oral and Subcutaneous (Individual and Family Plans)
- Intestinal and Multivisceral Transplantation
- Intraarticular Hyaluronic Acid Derivatives
- Isavuconazonium (Oral)
- Itraconazole (Tolsura®)
- Ixekizumab
- Laboratory Testing for Transplantation Rejection
- L-glutamine Oral Powder for Individual and Family Plans
- Lonapegsomatropin
- Medication Administration Site of Care
- Metyrosine
- Mifepristone (Korlym®)
- Musculoskeletal Imaging Guidelines
- Mycapssa
- Neck Imaging Guidelines
- Nintedanib
- Nitazoxanide for Individual and Family Plans
- Occupational Therapy (CPG 155)
- Octreotide IR (Non-Oncology Indications)
- Omalizumab
- Oncology Imaging Amendment to Cigna-eviCore General Oncology Imaging Guideline
- Oncology Imaging Guidelines
- Oncology Imaging Guidelines
- Oncology Medications Policy
- Opioid Therapy
- Oral Cancer Screening Systems
- Osilodrostat
- Oteseconazole
- Oxandrolone
- Oxybate
- Pacemakers (CID) Guidelines
- Pediatric Abdomen Imaging Guidelines
- Pediatric Abdomen Imaging Guidelines
- Pediatric Cardiac Imaging Guidelines
- Pediatric Chest Imaging Guidelines
- Pediatric Head Imaging Guidelines
- Pediatric Intensive Feeding Programs
- Pediatric Musculoskeletal Imaging Guidelines
- Pediatric Neck Imaging Guidelines
- Pediatric Oncology and Special Populations Oncology Imaging Guidelines
- Pediatric Oncology Imaging Guidelines
- Pediatric Pelvis Imaging Guidelines
- Pediatric Peripheral Nerve Disorders (PND) Imaging Guidelines
- Pediatric Peripheral Vascular Disease (PVD) Guidelines
- Pediatric Peripheral Vascular Disease (PVD) Imaging Guidelines
- Pediatric Spine Imaging Guidelines
- Pegfilgrastim
- Pelvis Imaging Amendment to Cigna-eviCore General Pelvis Imaging Guideline
- Pelvis Imaging Guidelines
- Penicillamine
- Percutaneous Vertebroplasty, Kyphoplasty, and Sacroplasty
- Peripheral Nerve Disorders Imaging Guidelines
- Peripheral Vascular Disease (PVD) Imaging Guidelines
- Pharmacy Prior Authorization
- Physical Therapy (CPG 135)
- Preface to the Imaging Guidelines
- Preventive Care Services
- Pulmonary Hypertension (PH) Therapy
- Pulmonary Hypertension (PH) Therapy
- Quantity Limitations
- Quazepam for Individual and Family Plans
- Ranolazine
- Rhinoplasty, Vestibular Stenosis Repair and Septoplasty
- Rifaximin for Individual and Family Plans
- Risankizumab Intravenous
- Risankizumab Subcutaneous
- Romosozumab
- Sandostatin LAR Depot (Non-Oncology Indications)
- Sapropterin
- Secukinumab
- Sirolimus
- Skeletal Muscle Relaxants
- Sleep Disordered Breathing Diagnosis & Treatment
- Sodium thiosulfate
- Somatropin
- Spesolimab
- Spine Imaging Guidelines
- Stem Cell Transplantation: Non-cancer Disorders
- Step Therapy – Legacy Prescription Drug Lists (Employer Group Plans)
- Step Therapy – Standard and Performance Prescription Drug Lists (Employer Group Plans)
- Step Therapy – Value and Advantage Prescription Drug Lists (Employer Group Plans)
- Step Therapy Individual and Family Plan
- Tapinarof
- Tascenso ODT
- Temporomandibular Joint (TMJ) Disorder Surgery
- Tetrabenazine
- Tezepelumab
- Thalidomide Non-Oncology Uses
- Tildrakizumab
- Tobramycin/loteprednol etabonate (Zylet) Ophthalmic Suspension for Individual and Family Plans
- Tolvaptan for Individual and Family Plans
- Topical Alpha Adrenergic Agonists
- Topical Corticosteroids
- Topical Estrogen Products (Non-Patch)
- Transcatheter Heart Valve Procedures
- Transdermal Estrogen and Estrogen-Progestin Patches
- Treatment of Gender Dysphoria
- Trientine Hydrochloride
- Ustekinumab Intravenous
- Ustekinumab Subcutaneous
- Vaginal Estrogen Products and Ospemifine
- Vagus Nerve Stimulation (VNS)
- Valbenazine
- Vedolizumab
- Ventricular Assist Devices (VADs), Percutaneous Cardiac Support Systems and Total Artificial Heart
- Voriconazole (Oral)
Click here to view the Cigna Medical Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
